Objective: Apatinib is a drug for the treatment of gastric cancer. In recent years, studies have found that it also has good efficacy in the treatment of lung adenocarcinoma, but its mechanism of action is still not clear. Therefore, this study uses bioinformatics and Experimental verification explores the mechanism of apatinib in the treatment of lung adenocarcinoma. To explore the potential biological targets of apatinib against lung adenocarcinoma based on weighted gene co-expression network analysis (WGCNA). Methods: The PharmMapper server was first used to reversely predict the potential targets of apatinib. Subsequently, it was combined with WGCNA to mine the GSE10072 data set in the GEO database of the National Center for Biotechnology Information (NCBI) to obtain the co-expressed gene module. Next, it was combined with apatinib Predict the target matching mapping to obtain the potential anti-lung adenocarcinoma target of apatinib. The STRING database was combined with Cytoscape software to visualize the protein interaction network of apatinib's potential anti-lung adenocarcinoma target protein and perform network topology analysis, as well as to obtain the core target from the network. Kaplan Meier plotter database was applied to analyze the relationship between key genes and the prognosis of patients with lung adenocarcinoma. Molecular docking technology was used for the potential of apatinib. Anti-lung adenocarcinoma target protein was finally verified by molecular interaction. Finally, Western blot was employed to analyze the expression level of the key target protein. Results: A total of 300 targets of apatinib were obtained, and 50 potential targets of apatinib against lung adenocarcinoma were screened. From the protein interaction network analysis, the key genes included CASP3, EGFR, MMP9, SRC, CASP8, CASP9, STAT3 and MAPK1. High expression of EGFR, SRC, MAPK1 and STAT3, and low expression of CASP3, CASP8, CASP9 and MMP9 were closely related to poor prognosis of patients with lung adenocarcinoma. Molecular docking showed that the interaction of apatinib with the targets of MAPK1, CASP3, EGFR, SRC, MMP9 and STAT3 was comparable to the positive control. Western blot showed that with the increasing of drug concentration, STAT3 were down-regulated, and CASP8 were up-regulated. Conclusion: The mechanism of apatinib in the treatment of lung adenocarcinoma is mainly through the regulation of the signal transduction pathway and the apoptosis pathway, which provides a scientific basis for the study of its anti-lung adenocarcinoma mechanism.
| Published in | Science Journal of Clinical Medicine (Volume 10, Issue 2) |
| DOI | 10.11648/j.sjcm.20211002.17 |
| Page(s) | 52-64 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Bioinformatics, Apatinib, Lung Adenocarcinoma, Biomarker, Molecular Docking
| [1] | Chen, W. Q., Li, N., Shi, J. F. (2019). Progress of Cancer Screening Program in Urban China. China Cancer, 28 (01): 1-11. |
| [2] | Zheng, Y. Z., Ma, R., Zhou, J. K. (2016). ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma. Scientific Reports, 6, 36447. |
| [3] | Siegel, R., Naishadham, D., Jemal, A. (2013). Cancer statistics, 2013 O-CA Cancer. Cin, 63 (1): 1-30. |
| [4] | Pan, C. X. (2019). Progress in targeted treatment of non-small cell lung cancer. Internal Medicine, 014 (003): 328-332. |
| [5] | Cai, Z. J., Liu, Q. (2021). Understanding the Global Cancer Statistics 2018: implications for cancer control. Science China (Life Sciences), 64 (06): 1017-1020. |
| [6] | Wei, X., Lai, Y., Li, J. (2017). PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology, 6 (3): e1284722. |
| [7] | Zhang, Y. R., Zhang, T. B., Tong, D. J. Apatinib-reated gastrie cancer listing N. Science and Technology Daily. 20141108. |
| [8] | Zhang, H. J. (2015). Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther, 9, 6075-6081. |
| [9] | Jia, J. H., Wang, J., Gao, P. (2019). Short term efficacy and prognosis of apatinib in the treatment of metastatic colorectal cancer with chemotherapy failure. Chinese Clinical Oncology, 46 (15): 785-789. |
| [10] | Hu, X. C., Cao, J., Hu, W. W. (2014). Multicenter phase II study of Apatinib in nontriple-negative metastatic breast cancer. BMC Cancer, 14 (1): 820. |
| [11] | Zhang, L., Shi, M. Q., Huang, C. (2012). A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. J ClinOncol, 30 (15): 7548-7548. |
| [12] | Li, X, Zhang, C. C., Tan, H. Y. (2016). Clinical effect of apatinib mesylate tablets in the treatment of advanced non-small cell lung cancer. Chinese Journal of biochemical medicine, 36 (2): 91-93. |
| [13] | Fang, S. C., Zhang, H. T., Zhang, Y. M. (2017). Apatinib as post secondline therapy in EGFR wild-type and Alk-negative advanced lung adenocarcinoma. Onco Targets Ther, 18 (10): 447-452. |
| [14] | Zhao, M. F. (2015). One case of advanced non-small cell lung cancer treated with apatinib. China Medical News, 30 (16): 18. |
| [15] | Peter, L. F., Steve, H. (2008). WGCNA: an R package for weighted correlation network analysis. 9 (2): 1-32. |
| [16] | Kuang HF, Hu YL. (2018) Mining prostate cancer development related genes with different levels of prostate specific antigen based on co expression network. Journal of Snake, 30 (02): 172-175. |
| [17] | Qi GQ, Kong W, Mou XY, Wang SQ. (2019). A new method for excavating feature lncRNA in lung adenocarcinoma based on pathway crosstalk analysis. Journal of Cellular Biochemistry, 120 (6): 9034-9046. |
| [18] | An Y, Zhang Q, Li X. (2018). Upregulated microRNA miR-21 promotes the progression of lung adenocarcinoma through inhibition of KIBRA and the Hippo signaling pathway. Biomedicine & Pharmacotherapy, 108, 1845-1855. |
| [19] | Wilhite, S. E., Barrett, T. (2012). Strategies to Explore Functional Genomics Data Sets in NCBI's GEO Database. Methods in Molecular Biology, 802: 41. |
| [20] | Zhou WX, Wang TX, Chen XR. (2016). Network analysis technology in network pharmacology. Journal of International Pharmaceutical Research, 43 (03): 399-409. |
| [21] | Wu LH, Wang Y, Fang XH. (2011). Network pharmacology technology tools: network visualization and network analysis. China Journal of Chinese Materia Medica, 36 (21): 2923-2925. |
| [22] | Li JH, Hu A, Zheng WJ, Hua ZC. (2014). Screening of target protein of triptolide on psoriasis by molecular docking. Chin Pharm J, 49 (13): 1133-1138. |
| [23] | Strachan, R. T., Ferrara, G., Roth, B. L. (2006) Screening the receptorome: An efficient approach for drug discovery and target validation. Drug Discovery Today, 11 (1516): 708-716. |
| [24] | Morris, G. M., Huey, R., Lindstrom, W. (2009). Autodock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry, 30 (16): 2785-2791. |
| [25] | Li HJ, LiY, Hao HS. (2012). Relationship between epidermal growth factor receptor and lung development. Hereditas, (01): 27-32. |
| [26] | Kim, J., Yoo, C., Moon, J. H., Um, S. H. (2020) EGFR Fragmentation for Topological Transformation Nanobarcoding. Chembiochem: a European journal of chemical biology, 21 (17): 2533-2539. |
| [27] | Chen, E. H., Chen, Z. C., Chen, M. L., & Che, M. Y. (2017). Clinical effect evaluation of apatinib mesylate tablets in the treatment of advanced non-small cell lung cancer. China Modern Medicine. |
| [28] | Yw, A., Pt, B., Lei, X. C., Li, L. A., Rui, H. A., & Mz, A. (2020). The clinical efficacy of combinatorial therapy of egfr-tki and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy-sciencedirect. Lung Cancer, 146, 165-173. |
| [29] | Li, F., Zhu, T., Cao, B., Wang, J., & Liang, L. (2017). Apatinib enhances antitumour activity of egfr-tkis in non-small cell lung cancer with egfr-tki resistance. European Journal of Cancer, 84, 184-192. |
| [30] | Peng, Y., Cui, H., Liu, Z., Liu, D., Liu, F., & Song, Y. (2017). Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown egfr status: a case report. Oncotargets & Therapy, 10, 2289-2295. |
| [31] | Lin, C., Wang, S. S, Xie W. W.,... & Chang J. H. (2016). Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget, 7 (37): 59236-59244. |
| [32] | Zhang, Q., Yu, Z. C., Bo, L., Zhang, H. M. (2019). The mechanism of apatinib on the proliferation and apoptosis of human hepatoma cells. Progress in Modern Biomedicine, 19 (13): 2424-2428. |
| [33] | Yang, J. M., Li, J. L. (2020). Effects of apatinib mesylate on proliferation, apoptosis and PI3K / Akt signaling pathway in human colon cancer HCT-116 cells. Hebei Medical Journal, 42 (02): 212-215. |
| [34] | Liu, Z. L., Jin, B. J., Cheng, C. G., Zhang, F. X., Wang, S. W., & Wang, Y., et al. (2017). Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway. European Review for Medical & Pharmacological Sciences, 21 (23): 5370. |
| [35] | Lee, H. J., Lee, E. K., Seo, Y. E. (2017). Roles of Beh2 and CASP9 and-3 in Cix30-induced human eosinophil apopto-sis. Microbiol Immunol Infect, 50 (2): 145-152. |
| [36] | Fornari, F., Utri, D., Patrizi, C. (2017). In Hepatocellular Carcinoma MIR 221 Modulates Sorafenib Resistance through Inhibition of CASP3 Mediated Apoptosis. Clin Cancer Res, 23 (14): 3953-3965. |
| [37] | Wang, X. S., Uok, J., Bella, A. E. (2014). CASP 3 expression in metastatic lymph nodes of esophageal squamous cell carcinoma is prognostic of vival. World J Gastroenterol, 20 (15): 4414-4420. |
| [38] | Chui, T. L., Su, C. C. (2017). Tanshinone II A increases proteinexpression levels of PERK, ATF6, IRELA, CHOP CASP 3 and CASP12 in pancreatic cancer BXPC-3 cell derived xenograft tumors. Mol Med Rep, 15 (5): 3259-3263. |
| [39] | Mou, Z., Xu, X., Dong, M., Xu, J. (2016). MICRORNA-148B acts as a tumor suppressor in cervical cancer by Inducing gi/sphase cell cycle arrest and apoptosis in a CASP 3-dependent manner. Med Sci Monit, 22: 2809-2815. |
| [40] | Huang, K., Cui, G. H., Zhao, S. (2012). Expression and relationship of BAG-1 and CASP 3 genes in non-small cell lung cancer. Chinese Journal of Gerontology, 32 (04): 696-697. |
| [41] | Xiao, L. N., Zhou, X. R., Zhang, Q. H. (2019). Expression of CASP 3 protein in non-small cell lung cancer and its relationship with tumor cell apoptosis. Laboratory Medicine and Clinic, 16 (14): 2034-2036+2041. |
| [42] | Liu, T. L., Wang, B., Zhao, J. J. (2010). Expression and significance of agglomeratin and CASP 3 in non-small cell lung cancer. Chinese Clinical Oncology, 15 (08): 712-716. |
| [43] | Marx V. (2013). Tracking metast asisand tricking cancer. Nature, 494 (7435): 13-6. |
| [44] | Shibasaki, K., & Rahman, A. (2013). Auxin and Temperature Stress: Molecular and Cellular Perspectives. |
| [45] | Tian, Wen, Yong, S., Zhang, Jing, H., & Ji, J. (2018). Comprehensive Analysis of DNA Methylation and Gene Expression Datasets Identified MMP9 and TWIST1 as Important Pathogenic Genes of Lung Adenocarcinoma. DNA AND CELL BIOLOGY. |
| [46] | Dorenkamp, M., Jrg P. Müller, Shanmuganathan, K. S., Schulten, H., N Müller, & Lffler, I. (2018). Hyperglycaemia-induced methylglyoxal accumulation potentiates VEGF resistance of diabetic monocytes through the aberrant activation of tyrosine phosphatase SHP-2/SRC kinase signalling axis. Scientific Reports, 8 (1): 14684-95. |
| [47] | Yao, Xiao, J., Xun, Wang, Fu, Q., & Meng. (2017). Inhibition of invasion by N-trans-feruloyloctopamine via AKT, p38MAPK O crossMark and EMT related signals in hepatocellular carcinoma cells. Bioorganic and Medicinal Chemistry Letters, 27 (4): 989-993. |
| [48] | Zhang, Y. M., & Zhang, L. Y. (2019). Knockdown of LASP2 inhibits the proliferation, migration, and invasion of cervical cancer cells. Journal of Cellular Biochemistry, 120 (9): 15389-15396. |
| [49] | Sorgen, P. L., Duffy, H. S., Sahoo, P., Coombs, W., Delmar, M. & Spray, D. C. (2004). Structural Changes in the Carboxyl Terminus of the Gap Junction Protein Connexin43 Indicates Signaling between Binding Domains for c-Src and Zonula Occludens-1. Journal of Biological Chemistry. 279 (52): 54695-701. |
| [50] | Zhen, R., Qin, X. S., Sei, J. Y. (2006). Effect of inhibition of SRC tyrosine kinase on proliferation of non-small cell lung cancer cells. Chinese Journal of Cancer Prevention and Treatment, 11 (1): 826-30. |
| [51] | Tobias, B., Hendrik, L., Frank, G. & Hendrik, U. (2012). The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells. Cancer Chemotherapy and Pharmacology. 34 (6): 175-6. |
| [52] | Ruan, Y., Gong, H., Li, Y. W., Zhang, H. B., Li, Y. (2019). Effect of apatinib on invasion and migration of lung cancer cells and its mechanism. Chinese Journal of Lung Cancer, 22 (05): 16-22. |
| [53] | Yang, S. H., Sharrocks, A. D., Whitmarsh, A. J. (2013). MAP kinase signalling cascades and transcriptional regulation. Gene, 513 (1): 3-21. |
| [54] | Kim, E. K., Choi, E. J. (2015) Compromised MAPK signaling in human diseases: an update. Archives of Toxicology, 89 (6): 867-882. |
| [55] | Morikawa, T., Baba, Y., Yamauchi, M.,... & Ogino, S. J. (2011). STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers.. Clinical cancer research: an official journal of the American Association for Cancer Research. 17 (6): 1452-1462. |
| [56] | Geiger, J. L., Grandis, J. R., Bauman, J. E. (2016). The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncology, 56: 84-92. |
| [57] | Liu, A. G, Liu, Y., Jin, Z. G.,... & Jiayuh Lin. (2017). XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PLoS ONE, 7 (10): e46624. |
| [58] | Hu, C., Zhuang, W., Qiao, Y., Liu, B., Liu, L., & Hui, K., et al. (2019). Effects of combined inhibition of STAT3 and WEGFR2 pathways on the radiosensitivity of non-small-cell lung cancer cells. OncoTargets and Therapy, Volume 12, 933-944. |
APA Style
Zhang Yanli, Luo Shiqiong, Zhong Yixuan, Wu Guosong, Zhang Zhidong. (2021). Identification of Functional Gene Modules and Biomarkers of Apatinib Against Lung Adenocarcinoma Based on Weighted Gene Co-expression Network Ansalysis (WGCNA). Science Journal of Clinical Medicine, 10(2), 52-64. https://doi.org/10.11648/j.sjcm.20211002.17
ACS Style
Zhang Yanli; Luo Shiqiong; Zhong Yixuan; Wu Guosong; Zhang Zhidong. Identification of Functional Gene Modules and Biomarkers of Apatinib Against Lung Adenocarcinoma Based on Weighted Gene Co-expression Network Ansalysis (WGCNA). Sci. J. Clin. Med. 2021, 10(2), 52-64. doi: 10.11648/j.sjcm.20211002.17
AMA Style
Zhang Yanli, Luo Shiqiong, Zhong Yixuan, Wu Guosong, Zhang Zhidong. Identification of Functional Gene Modules and Biomarkers of Apatinib Against Lung Adenocarcinoma Based on Weighted Gene Co-expression Network Ansalysis (WGCNA). Sci J Clin Med. 2021;10(2):52-64. doi: 10.11648/j.sjcm.20211002.17
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjcm.20211002.17,
author = {Zhang Yanli and Luo Shiqiong and Zhong Yixuan and Wu Guosong and Zhang Zhidong},
title = {Identification of Functional Gene Modules and Biomarkers of Apatinib Against Lung Adenocarcinoma Based on Weighted Gene Co-expression Network Ansalysis (WGCNA)},
journal = {Science Journal of Clinical Medicine},
volume = {10},
number = {2},
pages = {52-64},
doi = {10.11648/j.sjcm.20211002.17},
url = {https://doi.org/10.11648/j.sjcm.20211002.17},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20211002.17},
abstract = {Objective: Apatinib is a drug for the treatment of gastric cancer. In recent years, studies have found that it also has good efficacy in the treatment of lung adenocarcinoma, but its mechanism of action is still not clear. Therefore, this study uses bioinformatics and Experimental verification explores the mechanism of apatinib in the treatment of lung adenocarcinoma. To explore the potential biological targets of apatinib against lung adenocarcinoma based on weighted gene co-expression network analysis (WGCNA). Methods: The PharmMapper server was first used to reversely predict the potential targets of apatinib. Subsequently, it was combined with WGCNA to mine the GSE10072 data set in the GEO database of the National Center for Biotechnology Information (NCBI) to obtain the co-expressed gene module. Next, it was combined with apatinib Predict the target matching mapping to obtain the potential anti-lung adenocarcinoma target of apatinib. The STRING database was combined with Cytoscape software to visualize the protein interaction network of apatinib's potential anti-lung adenocarcinoma target protein and perform network topology analysis, as well as to obtain the core target from the network. Kaplan Meier plotter database was applied to analyze the relationship between key genes and the prognosis of patients with lung adenocarcinoma. Molecular docking technology was used for the potential of apatinib. Anti-lung adenocarcinoma target protein was finally verified by molecular interaction. Finally, Western blot was employed to analyze the expression level of the key target protein. Results: A total of 300 targets of apatinib were obtained, and 50 potential targets of apatinib against lung adenocarcinoma were screened. From the protein interaction network analysis, the key genes included CASP3, EGFR, MMP9, SRC, CASP8, CASP9, STAT3 and MAPK1. High expression of EGFR, SRC, MAPK1 and STAT3, and low expression of CASP3, CASP8, CASP9 and MMP9 were closely related to poor prognosis of patients with lung adenocarcinoma. Molecular docking showed that the interaction of apatinib with the targets of MAPK1, CASP3, EGFR, SRC, MMP9 and STAT3 was comparable to the positive control. Western blot showed that with the increasing of drug concentration, STAT3 were down-regulated, and CASP8 were up-regulated. Conclusion: The mechanism of apatinib in the treatment of lung adenocarcinoma is mainly through the regulation of the signal transduction pathway and the apoptosis pathway, which provides a scientific basis for the study of its anti-lung adenocarcinoma mechanism.},
year = {2021}
}
TY - JOUR T1 - Identification of Functional Gene Modules and Biomarkers of Apatinib Against Lung Adenocarcinoma Based on Weighted Gene Co-expression Network Ansalysis (WGCNA) AU - Zhang Yanli AU - Luo Shiqiong AU - Zhong Yixuan AU - Wu Guosong AU - Zhang Zhidong Y1 - 2021/06/25 PY - 2021 N1 - https://doi.org/10.11648/j.sjcm.20211002.17 DO - 10.11648/j.sjcm.20211002.17 T2 - Science Journal of Clinical Medicine JF - Science Journal of Clinical Medicine JO - Science Journal of Clinical Medicine SP - 52 EP - 64 PB - Science Publishing Group SN - 2327-2732 UR - https://doi.org/10.11648/j.sjcm.20211002.17 AB - Objective: Apatinib is a drug for the treatment of gastric cancer. In recent years, studies have found that it also has good efficacy in the treatment of lung adenocarcinoma, but its mechanism of action is still not clear. Therefore, this study uses bioinformatics and Experimental verification explores the mechanism of apatinib in the treatment of lung adenocarcinoma. To explore the potential biological targets of apatinib against lung adenocarcinoma based on weighted gene co-expression network analysis (WGCNA). Methods: The PharmMapper server was first used to reversely predict the potential targets of apatinib. Subsequently, it was combined with WGCNA to mine the GSE10072 data set in the GEO database of the National Center for Biotechnology Information (NCBI) to obtain the co-expressed gene module. Next, it was combined with apatinib Predict the target matching mapping to obtain the potential anti-lung adenocarcinoma target of apatinib. The STRING database was combined with Cytoscape software to visualize the protein interaction network of apatinib's potential anti-lung adenocarcinoma target protein and perform network topology analysis, as well as to obtain the core target from the network. Kaplan Meier plotter database was applied to analyze the relationship between key genes and the prognosis of patients with lung adenocarcinoma. Molecular docking technology was used for the potential of apatinib. Anti-lung adenocarcinoma target protein was finally verified by molecular interaction. Finally, Western blot was employed to analyze the expression level of the key target protein. Results: A total of 300 targets of apatinib were obtained, and 50 potential targets of apatinib against lung adenocarcinoma were screened. From the protein interaction network analysis, the key genes included CASP3, EGFR, MMP9, SRC, CASP8, CASP9, STAT3 and MAPK1. High expression of EGFR, SRC, MAPK1 and STAT3, and low expression of CASP3, CASP8, CASP9 and MMP9 were closely related to poor prognosis of patients with lung adenocarcinoma. Molecular docking showed that the interaction of apatinib with the targets of MAPK1, CASP3, EGFR, SRC, MMP9 and STAT3 was comparable to the positive control. Western blot showed that with the increasing of drug concentration, STAT3 were down-regulated, and CASP8 were up-regulated. Conclusion: The mechanism of apatinib in the treatment of lung adenocarcinoma is mainly through the regulation of the signal transduction pathway and the apoptosis pathway, which provides a scientific basis for the study of its anti-lung adenocarcinoma mechanism. VL - 10 IS - 2 ER -
Information
Email: